BioCentury
ARTICLE | Clinical News

Masitinib: Phase II amended

November 11, 2013 8:00 AM UTC

AB Science amended an ongoing, double-blind, placebo-controlled, European Phase II trial of oral masitinib plus riluzole to designate it as a Phase III trial and increase enrollment to 210 patients fr...